Article Text

Download PDFPDF
Warning on use of ondansetron in first trimester of pregnancy

Abstract

Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.

  • healthcare quality, access, and evaluation
  • primary healthcare
View Full Text

Statistics from Altmetric.com

Footnotes

  • Overview of: European Medicines Agency Pharmacovigilance Risk Assessment Committee. Updated signal assessment report on birth defects following in-utero exposure during the first trimester of pregnancy arising from recent publications with ondansetron. EMA/PRAC/347675/2019

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.